Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 22 | 2024 | 309 | 4.450 |
Why?
|
| Infection Control | 15 | 2024 | 173 | 3.090 |
Why?
|
| Enterobacteriaceae Infections | 8 | 2021 | 57 | 2.280 |
Why?
|
| Klebsiella pneumoniae | 10 | 2022 | 71 | 1.940 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 5 | 2021 | 20 | 1.790 |
Why?
|
| beta-Lactamases | 12 | 2025 | 101 | 1.750 |
Why?
|
| Bacteremia | 6 | 2019 | 100 | 1.580 |
Why?
|
| Bacterial Proteins | 10 | 2025 | 91 | 1.530 |
Why?
|
| Intensive Care Units | 9 | 2024 | 265 | 1.470 |
Why?
|
| Klebsiella Infections | 9 | 2022 | 65 | 1.460 |
Why?
|
| Medical Informatics | 2 | 2021 | 10 | 1.240 |
Why?
|
| Population Surveillance | 6 | 2018 | 115 | 1.240 |
Why?
|
| Staphylococcal Infections | 4 | 2018 | 166 | 1.140 |
Why?
|
| Carrier State | 7 | 2024 | 62 | 1.060 |
Why?
|
| Clostridium Infections | 2 | 2023 | 24 | 1.040 |
Why?
|
| Public Health Surveillance | 2 | 2021 | 11 | 0.870 |
Why?
|
| Catheter-Related Infections | 3 | 2014 | 22 | 0.860 |
Why?
|
| Skin | 5 | 2025 | 130 | 0.850 |
Why?
|
| Hospitals | 12 | 2024 | 170 | 0.850 |
Why?
|
| Humans | 51 | 2025 | 27307 | 0.840 |
Why?
|
| Communicable Diseases | 1 | 2023 | 23 | 0.830 |
Why?
|
| Disease Outbreaks | 3 | 2022 | 81 | 0.790 |
Why?
|
| Virus Diseases | 1 | 2022 | 11 | 0.770 |
Why?
|
| Subacute Care | 1 | 2021 | 6 | 0.750 |
Why?
|
| Chlorhexidine | 4 | 2024 | 64 | 0.660 |
Why?
|
| Disease Notification | 2 | 2018 | 5 | 0.660 |
Why?
|
| Skilled Nursing Facilities | 5 | 2021 | 31 | 0.630 |
Why?
|
| Baths | 3 | 2024 | 31 | 0.630 |
Why?
|
| Pyomyositis | 2 | 2009 | 5 | 0.600 |
Why?
|
| Chicago | 12 | 2024 | 953 | 0.600 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2024 | 73 | 0.540 |
Why?
|
| Carbapenems | 6 | 2021 | 46 | 0.540 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2018 | 120 | 0.530 |
Why?
|
| Enterobacteriaceae | 2 | 2015 | 45 | 0.520 |
Why?
|
| Blastomycosis | 2 | 2020 | 24 | 0.470 |
Why?
|
| Hospital Information Systems | 1 | 2014 | 5 | 0.460 |
Why?
|
| Illinois | 7 | 2021 | 250 | 0.460 |
Why?
|
| Health Facilities | 2 | 2024 | 26 | 0.420 |
Why?
|
| Candidiasis | 2 | 2021 | 28 | 0.420 |
Why?
|
| Patient Care | 1 | 2013 | 31 | 0.410 |
Why?
|
| Male | 22 | 2025 | 14887 | 0.390 |
Why?
|
| Middle Aged | 17 | 2024 | 9068 | 0.380 |
Why?
|
| Community-Acquired Infections | 2 | 2012 | 69 | 0.370 |
Why?
|
| Candida | 2 | 2021 | 19 | 0.350 |
Why?
|
| Anti-Bacterial Agents | 4 | 2024 | 380 | 0.350 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 31 | 0.340 |
Why?
|
| Vancomycin Resistance | 1 | 2010 | 29 | 0.340 |
Why?
|
| Ecosystem | 2 | 2021 | 24 | 0.340 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2010 | 55 | 0.330 |
Why?
|
| Registries | 3 | 2020 | 201 | 0.330 |
Why?
|
| Nursing Homes | 3 | 2025 | 42 | 0.330 |
Why?
|
| Disease Transmission, Infectious | 2 | 2021 | 20 | 0.320 |
Why?
|
| Extremities | 1 | 2009 | 26 | 0.310 |
Why?
|
| Blastomyces | 1 | 2009 | 12 | 0.310 |
Why?
|
| Female | 19 | 2025 | 15334 | 0.310 |
Why?
|
| Aged | 15 | 2025 | 9120 | 0.310 |
Why?
|
| Prevalence | 5 | 2018 | 458 | 0.300 |
Why?
|
| Adult | 13 | 2024 | 7945 | 0.300 |
Why?
|
| Neutropenia | 1 | 2008 | 16 | 0.300 |
Why?
|
| Public Health | 2 | 2021 | 71 | 0.290 |
Why?
|
| Retrospective Studies | 6 | 2023 | 3551 | 0.290 |
Why?
|
| Anus Diseases | 1 | 2008 | 2 | 0.290 |
Why?
|
| Ulcer | 1 | 2008 | 7 | 0.290 |
Why?
|
| Staphylococcus aureus | 1 | 2008 | 73 | 0.280 |
Why?
|
| United States | 7 | 2023 | 2078 | 0.270 |
Why?
|
| Pulmonary Embolism | 1 | 2008 | 63 | 0.270 |
Why?
|
| Sepsis | 1 | 2008 | 115 | 0.260 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2024 | 51 | 0.250 |
Why?
|
| Candida glabrata | 1 | 2005 | 3 | 0.250 |
Why?
|
| Fungemia | 1 | 2005 | 8 | 0.250 |
Why?
|
| Critical Illness | 2 | 2018 | 120 | 0.240 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 34 | 0.240 |
Why?
|
| Critical Care | 2 | 2023 | 122 | 0.220 |
Why?
|
| Hospitalization | 3 | 2024 | 315 | 0.210 |
Why?
|
| Bacterial Infections | 1 | 2024 | 54 | 0.210 |
Why?
|
| Multilocus Sequence Typing | 2 | 2021 | 17 | 0.210 |
Why?
|
| Patients | 1 | 2023 | 33 | 0.200 |
Why?
|
| Hospital Administration | 2 | 2021 | 25 | 0.200 |
Why?
|
| Long-Term Care | 4 | 2017 | 61 | 0.200 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 147 | 0.190 |
Why?
|
| Catheterization, Central Venous | 2 | 2014 | 37 | 0.180 |
Why?
|
| Genomics | 4 | 2023 | 68 | 0.180 |
Why?
|
| Phylogeny | 1 | 2021 | 54 | 0.180 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2021 | 87 | 0.180 |
Why?
|
| Computers | 1 | 2021 | 17 | 0.180 |
Why?
|
| Dermatomycoses | 1 | 2021 | 5 | 0.180 |
Why?
|
| Occupational Exposure | 1 | 2021 | 18 | 0.180 |
Why?
|
| Rectum | 5 | 2024 | 52 | 0.180 |
Why?
|
| Clinical Protocols | 1 | 2021 | 58 | 0.170 |
Why?
|
| Epidemiological Monitoring | 2 | 2024 | 15 | 0.170 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 55 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 675 | 0.170 |
Why?
|
| Algorithms | 2 | 2014 | 352 | 0.170 |
Why?
|
| Pandemics | 1 | 2022 | 243 | 0.170 |
Why?
|
| Otitis Media | 1 | 2020 | 5 | 0.160 |
Why?
|
| Health Personnel | 1 | 2021 | 99 | 0.160 |
Why?
|
| Skull Base | 1 | 2020 | 35 | 0.160 |
Why?
|
| Quality Improvement | 2 | 2024 | 140 | 0.150 |
Why?
|
| Patient Transfer | 2 | 2024 | 26 | 0.150 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2018 | 41 | 0.150 |
Why?
|
| Risk Factors | 4 | 2021 | 2335 | 0.140 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 4841 | 0.140 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 146 | 0.140 |
Why?
|
| Time Factors | 2 | 2013 | 1444 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 162 | 0.130 |
Why?
|
| Mass Screening | 1 | 2018 | 174 | 0.130 |
Why?
|
| Health Information Exchange | 1 | 2015 | 4 | 0.120 |
Why?
|
| Drug Resistance, Microbial | 1 | 2015 | 67 | 0.120 |
Why?
|
| Management Audit | 1 | 2014 | 2 | 0.120 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 17 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2010 | 1903 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2017 | 589 | 0.110 |
Why?
|
| Drug Resistance, Multiple | 1 | 2012 | 12 | 0.100 |
Why?
|
| Equipment Contamination | 1 | 2012 | 26 | 0.100 |
Why?
|
| Epidemiologic Methods | 1 | 2012 | 18 | 0.090 |
Why?
|
| Bias | 1 | 2012 | 30 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2016 | 1792 | 0.090 |
Why?
|
| Skin Care | 2 | 2024 | 16 | 0.090 |
Why?
|
| Ventilators, Mechanical | 2 | 2021 | 27 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2010 | 32 | 0.090 |
Why?
|
| Disease Reservoirs | 1 | 2010 | 9 | 0.090 |
Why?
|
| Single-Blind Method | 1 | 2010 | 101 | 0.090 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2010 | 8 | 0.090 |
Why?
|
| Hand Disinfection | 1 | 2010 | 25 | 0.090 |
Why?
|
| Research Design | 1 | 2012 | 189 | 0.080 |
Why?
|
| Enterococcus | 1 | 2010 | 55 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 133 | 0.080 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2009 | 1 | 0.080 |
Why?
|
| Hepatitis B Antibodies | 1 | 2009 | 2 | 0.080 |
Why?
|
| Hepatitis B | 1 | 2009 | 12 | 0.080 |
Why?
|
| Lung Diseases, Fungal | 1 | 2009 | 10 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 30 | 0.080 |
Why?
|
| Quadriceps Muscle | 1 | 2009 | 34 | 0.080 |
Why?
|
| Sentinel Surveillance | 1 | 2008 | 7 | 0.080 |
Why?
|
| Gram-Positive Cocci | 1 | 2008 | 4 | 0.070 |
Why?
|
| Gram-Negative Bacteria | 1 | 2008 | 26 | 0.070 |
Why?
|
| Hospitals, Urban | 1 | 2008 | 34 | 0.070 |
Why?
|
| Adolescent | 2 | 2018 | 2185 | 0.070 |
Why?
|
| Exotoxins | 1 | 2008 | 2 | 0.070 |
Why?
|
| Leukocidins | 1 | 2008 | 2 | 0.070 |
Why?
|
| Prostatic Diseases | 1 | 2008 | 2 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 161 | 0.070 |
Why?
|
| Bacterial Toxins | 1 | 2008 | 6 | 0.070 |
Why?
|
| Sexuality | 1 | 2008 | 14 | 0.070 |
Why?
|
| Methicillin Resistance | 1 | 2008 | 25 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2008 | 261 | 0.070 |
Why?
|
| Abscess | 1 | 2008 | 28 | 0.070 |
Why?
|
| Radiography | 1 | 2009 | 617 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2008 | 352 | 0.070 |
Why?
|
| Penicillanic Acid | 1 | 2005 | 3 | 0.060 |
Why?
|
| Piperacillin | 1 | 2005 | 3 | 0.060 |
Why?
|
| Fluconazole | 1 | 2005 | 7 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 383 | 0.060 |
Why?
|
| Models, Statistical | 2 | 2016 | 127 | 0.060 |
Why?
|
| Vancomycin | 1 | 2005 | 52 | 0.060 |
Why?
|
| Metagenomics | 1 | 2025 | 6 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 893 | 0.060 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2024 | 12 | 0.060 |
Why?
|
| Bacteria | 1 | 2025 | 73 | 0.060 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2024 | 57 | 0.060 |
Why?
|
| Universal Precautions | 1 | 2024 | 6 | 0.060 |
Why?
|
| Iodophors | 1 | 2024 | 5 | 0.060 |
Why?
|
| California | 1 | 2024 | 36 | 0.060 |
Why?
|
| Administration, Intranasal | 1 | 2024 | 29 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 903 | 0.060 |
Why?
|
| Feces | 1 | 2024 | 103 | 0.060 |
Why?
|
| HIV Infections | 1 | 2009 | 477 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 1108 | 0.050 |
Why?
|
| Animals | 1 | 2012 | 3681 | 0.050 |
Why?
|
| Microbiota | 1 | 2025 | 100 | 0.050 |
Why?
|
| Feedback | 1 | 2023 | 33 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2024 | 151 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2023 | 7 | 0.050 |
Why?
|
| Respiratory System | 1 | 2023 | 9 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 48 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2023 | 44 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 486 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 8 | 0.040 |
Why?
|
| Georgia | 1 | 2021 | 12 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 18 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1380 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2021 | 84 | 0.040 |
Why?
|
| Itraconazole | 1 | 2020 | 5 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 43 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2021 | 195 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2021 | 216 | 0.040 |
Why?
|
| Biopsy | 1 | 2020 | 201 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 141 | 0.040 |
Why?
|
| Integrons | 1 | 2018 | 4 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2018 | 47 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 350 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 350 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 69 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 1807 | 0.030 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2015 | 13 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 33 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 488 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 50 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2014 | 17 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 64 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 88 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 173 | 0.030 |
Why?
|
| Infant | 1 | 2015 | 517 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2014 | 114 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2015 | 562 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2012 | 13 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 2012 | 25 | 0.020 |
Why?
|
| Propensity Score | 1 | 2012 | 36 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 94 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2012 | 48 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 561 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 2032 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 277 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2012 | 109 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 1156 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2009 | 53 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2009 | 61 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 3540 | 0.020 |
Why?
|